NOW AVAILABLE

LOREEV XR™ (lorazepam) extended-release capsules: a new Once-Daily dosing option for the treatment of anxiety disorders in adults who are receiving stable, evenly divided, three times daily dosing with lorazepam tablets.1

Once-Daily pharmacokinetic profile1,2

LOREEV XR 3 mg Once-Daily vs lorazepam immediate-release (IR) tablets 1 mg q8h1,2
Curve ChartCurve Chart

Study design (N=48): Randomized, open-label, 2-way cross-over, 2-period, 2-sequence, 2-treatment, relative bioavailability study at steady state, with a 10-day washout period. Pharmacokinetic profile draws on day 8. Steady state was achieved by day 5.2

Steady-state 24-hour pharmacokinetic profile

Steady-state 24-hour pharmacokinetic profile

  • Median Tmax of 9 hours2
  • Minimal fluctuations throughout the day2
  • Bioequivalent to lorazepam tablets dosed q8h1,2

Once-Daily dosing1

Once-Daily dosing1

  • 1 mg, 2 mg, 3 mg extended-release capsules
  • Option to sprinkle dose
  • Dose in the mornings, with or without food

Metabolism of LOREEV XR

Metabolism of LOREEV XR

  • Lorazepam is not metabolized via the Cytochrome P450 isoenzyme pathway3
  • Lorazepam is metabolized via glucuronidation1,3
    • No active metabolites

Copay Card savings

Help eligible patients save on Once-Daily lorazepam with the LOREEV XR Copay Card1*

Applies only to commercially insured patients. Individual costs may vary. Program eligibility and restrictions apply.